Cost-effectiveness of vaccination against cervical cancer: A multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios

Vaccine

Volumn 26, Issue SUPPL.5, 2008, Pages

  Suárez, Eugenio ^a   Smith, Jennifer S ^b   Bosch, F Xavier ^c   Nieminen, Pekka ^d   Chen, Chien Jen ^e   Torvinen, Saku ^f   Demarteau, Nadia ^g   Standaert, Baudouin ^g  

^a UNIVERSITY OF CHILE   (Chile)

^b IL   (United States)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e ACADEMIA SINICA   (Taiwan)

^f GLAXOSMITHKLINE   (United Kingdom)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Cost effectiveness; HPV vaccines; Vaccination scenarios; Vaccine characteristics

Indexed keywords

CANCER VACCINE;

ADOLESCENT; ADULT; ALTERNATIVE MEDICINE; ARTICLE; CANCER IMMUNIZATION; CHILD; CHILE; COHORT ANALYSIS; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; FEMALE; FINLAND; HEALTH; HUMAN; IMMUNITY; IRELAND; POLAND; PRIORITY JOURNAL; PROBABILITY; TAIWAN; UTERINE CERVIX CANCER;

COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MODELS, ECONOMETRIC; NATIONAL HEALTH PROGRAMS; UTERINE CERVICAL NEOPLASMS;

EID: 50049101700     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.069     Document Type: Article

References (97)

1. Ferko N., Postma M., Gallivan S., Kruzikas D., and Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 26 Suppl 5 (2008) F3-F15
2. Debicki D., Ferko N., Demarteau N., Gallivan S., Bauch C., Anonychuk A., et al. Comparison of detailed and succint cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26 Suppl 5 (2008) F16-F28
3. Rogoza R.M., Ferko N., Bentley J., Meijer C.J.L.M., Berkhof J., Wang K.L., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine 26 Suppl 5 (2008) F46-F58
4. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
5. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 367 9518 (2006) 1247-1255
6. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 369 9576 (2007) 1861-1868
7. Gall SA, Teixeira J, Wheeler CM, Naud P, Harper DM, Franco EL, et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. (Abstract no. 4900 presented at the American Association for Cancer Research (AACR) annual meeting, April 14-18, Los Angeles, USA); 2007.
8. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
9. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (2006) 1459-1466
10. Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow-up through 6.4 years in women vaccinated with CervarixTM (GSK's HPV 16/18 AS04 candidate vaccine). (Late-breaking abstracts presented for the thirty-ninth annual meeting of the Society of Gynecologic Oncologists, 9-12 March, Tampa, U.S.A.). Gynecologic Oncology 2008 April;109(1):158.
11. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 26 (2007) 4931-4939
12. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 9 (2007) 5399-5408
13. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., and Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106 6 (2003) 896-904
14. Van De Velde N., Brisson M., and Boily M.C. Modeling human papillomavirus vaccine effectiveness: Quantifying the impact of parameter uncertainty. Am J Epidemiol 165 7 (2007) 762-775
15. Elbasha E.H., Dasbach E.J., and Insinga R. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 1 (2007) 28-41
16. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 1 (2003) 37-48
17. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 11 (2004) 1915-1923
18. Guidance for the introduction of HPV vaccines in EU countries. Stockholm: European Centre for Disease Prevention and Control; 2008.
19. Garnett G.P., Kim J.J., French K., and Goldie S.J. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 Suppl 3 (2006) S178-S186
20. Hughes J.P., Garnett G.P., and Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 13 6 (2002) 631-639
21. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 88 1 (2003) 63-73
22. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl. 3 (2006) S26-S34
23. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121 3 (2007) 621-632
24. Keam S.J., and Harper D.M. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix trademark]. Drugs 68 3 (2008) 359-372
25. Cost-effectiveness thresholds. World Health Organisation 2007. Available from: URL: http://www.who.int/choice/costs/CER_thresholds/en/index.html.
26. Fraser C., Tomassini J.E., Xi L., Golm G., Watson M., Giuliano A.R., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25 21 (2007) 4324-4333
27. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 2 (2004) 324-327
28. ® version September 1996. Newfield: Palisade Corporation; 1996.
29. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organisation; 2003.
30. David MP, Hardt K, Tibaldi F, Dubin G, Descamps D. Long-term persistence of detectable anti-HPV-16 and anti-HPV-18 antibodies induced by Cervarix(TM): Modelling of sustained antibody responses. (Abstract PS26-37 presented at the 24th International Papillomavirus Conference and Clinical Workshop, November 3-9, Beijing, China). s.l.: International Papillomavirus Society & Chinese Medical Association; 2007: p. 373.
31. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. The New Engl J Med 356 19 (2007) 1928-1943
32. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New Engl J Med 356 19 (2007) 1915-1927
33. Lawrence M.H., and Goldstein M.A. Hepatitis B immunization in adolescents. J Adolesc Health 17 4 (1995) 234-243
34. ®. http://www health gov au/internet/main/publishing nsf/Content/gardasil_hpv htm 2008 [cited 2008 April 15].
35. Favato G, Pieri V, Mills RW. Cost/effective analysis of anti-HPV vaccination programme in Italy: A multi-cohort Markov model. Henley-on-Thames: Henley Centre for Value Improvement (HCVI); 2007 February. Report No.: 13.
36. Brouwer W.B., Niessen L.W., Postma M.J., and Rutten F.F. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 331 7514 (2005) 446-448
37. Bos J.M., Beutels P., Annemans L., and Postma M.J. Valuing prevention through economic evaluation: Some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 22 18 (2004) 1171-1179
38. Brouwer W.B., and van Exel N.J. Discounting in decision making: The consistency argument revisited empirically. Health Policy 67 2 (2004) 187-194
39. West R.R. Economic rate of discount and estimating cost benefit of viral immunisation programmes. Rev Med Virol 9 1 (1999) 51-55
40. Bos J.M., Postma M.J., and Annemans L. Discounting health effects in pharmacoeconomic evaluations: Current controversies [article]. Pharmacoeconomics 23 7 (2005) 639-649
41. Wright T.C., Van D.P., Schmitt H.J., and Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine 24 Suppl 3 (2006) S122-S131
42. Bauch C, Anonychuk A, Fikre M, Pham B, Demarteau N. Herd protection effects in cost-effectiveness analysis of prophylactic cervical cancer vaccination. (Abstract no. PS19-42 presented at the 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China, 3-9 November); 2007:317.
43. French K.M., Barnabas R.V., Lehtinen M., Kontula O., Pukkala E., Dillner J., et al. Strategies for the introduction of human papillomavirus vaccination: Modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 96 3 (2007) 514-518
44. Stone K.M. Human papillomavirus infection and genital warts: Update on epidemiology and treatment. Clin Infect Dis 20 Suppl 1 (1995) S91-S97
45. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 5 (2005) 731-738
46. Beutner K.R., Wiley D.J., Douglas J.M., Tyring S.K., Fife K., Trofatter K., et al. Genital warts and their treatment. Clin Infect Dis 28 Suppl 1 (1999) S37-S56
47. Buck Jr. H.W. Genital warts. Clin Evid 15 (2006) 2149-2161
48. Fox P.A., and Tung M.Y. Human papillomavirus: Burden of illness and treatment cost considerations. Am J Clin Dermatol 6 6 (2005) 365-381
49. Lacey C.J., Lowndes C.M., and Shah K.V. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 Suppl 3 (2006) S35-S41
50. Langley P.C., White D.J., and Drake S.M. Patterns of treatment and resource utilization in the treatment of external genital warts in England and Wales. Int J STD AIDS 15 7 (2004) 473-478
51. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 1 (2006) 88-100
52. Fahey M.T., Irwig L., and Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 141 7 (1995) 680-689
53. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med 132 10 (2000) 810-819
54. Ministerio del Salud. Guía clínica cancer cervicouterino 2. 1st ed. Santiago: Minisal; 2005.
55. Suarez E, Prieto M. Cervical cancer: The Chilean perspective. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006 November;95 Suppl 1:S235-S238.
56. Monto K., and Nieminen P. Gynekologisten irtosolunäytteiden määrät ja raportointitavat Suomessa. Suomen Lääkärilehti (Finn Med J) 18-19 (2005) 2093-2097
57. Research Solutions market research conducted on behalf of GSK; 2006.
58. Koong S.L., Yen A.M., and Chen T.H. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 13 Suppl 1 (2006) S44-S47
59. Yen MS, Tang CH, You SL, Tsai IC, Ferko N, Habib MJ, et al. Clinical and cost impact of HPV vaccination in Taiwan, a country with high cervical cancer incidence. (Abstract no. P-477 presented at the 23rd International Papillomavirus Conference & Clinical Workshop, September 1-7, Prague, Czech Republic). Prague: Institute of Hematology and Blood Transfusion; 2006: p. 350.
60. Rash B, Prendiville W, Byrne P, Stratton J, Redmond S. The cost of treating and managing abnormal cervical conditions in Ireland. (Abstract PCN39 presented at the 10th International Society For Pharmacoeconomics And Outcomes Research (ISPOR) congress, Dublin, 20-23 October). Value in Health 2007;10(6):A334.
61. Helsingin ja Uudenmaan airaanhoitopiiri. Hinnasto 2006. (Official price list of Hospital District of Heslinki and Uusimaa); 2006.
62. Varsinais-Suomen sairaanhoitopiiri. Palveluhinnasto 2006. (Official price list of Hospital District of Southwest Finland, 2006). Available from http://www.vsshp.fi; 2006.
63. Jach R. dane z Pracowni cytologii i badan molekularnych CM UJ. Personal communication; 2007.
64. Tang CH, Tsai CH, Pwu RF, Wang HI, Chen CA, Hsie CY, et al. Treatment costs of cervical precancerous lesion and cervical cancer in Taiwan 2008; in preparation.
65. Ministry of Health C. National Health Fund (FONASA); 2007.
66. Working group set up by the Finnish Medical Society Duodecim and the Finnish Colposcopy Association. Diagnosis, treatment and follow-up of cytological changes in the cervix, vagina and vulva. http://wwwkaypahoitofi/kh/kaypahoito?suositus=ccs00018 2007.
67. Health Outcomes Data Repository. Cardiff Research Consortium 2007. Available from: URL: https://www.crc-limited.co.uk.
68. Insinga R, Glass A, Rush B. Health state transitions following an abnormal pap smear: Implications for health utility assessment in cost-effectiveness analyses. (Abstract W-02 presented at 22nd International Papillomavirus Conference & Clinical Workshop 2005, April 30-May 6, Vancouver, BC, Canada); 2005.
69. Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: Visual analog scale versus time trade-off elicitation. (Abstract no 542 presented at the Twenty-First International Papillomavirus Conference, México City, México, February 20-27); 2004.
70. Ferreccio C., Prado R.B., Luzoro A.V., Ampuero S.L., Snijders P.J., Meijer C.J., et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 13 12 (2004) 2271-2276
71. Beby-Defaux A., Bourgoin A., Ragot S., Battandier D., Lemasson J.M., Renaud O., et al. Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 73 2 (2004) 262-268
72. Boulanger J.C., Sevestre H., Bauville E., Ghighi C., Harlicot J.P., and Gondry J. Epidemiology of HPV infection. Gynecol Obstet Fertil 32 3 (2004) 218-223
73. Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7932 women. Br J Cancer 84 12 (2001) 1616-1623
74. Dalstein V., Riethmuller D., Sautiere J.L., Pretet J.L., Kantelip B., Schaal J.P., et al. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus. Eur J Cancer 40 8 (2004) 1225-1232
75. Riethmuller D., Gay C., Bertrand X., Bettinger D., Schaal J.P., Carbillet J.P., et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 8 3 (1999) 157-164
76. Kitchener H.C., Almonte M., Wheeler P., Desai M., Gilham C., Bailey A., et al. HPV testing in routine cervical screening: Cross sectional data from the ARTISTIC trial. Br J Cancer 95 1 (2006) 56-61
77. Gajewska M., Wielgos M., Kaminski P., Marianowski P., Malejczyk M., Majewski S., et al. The occurrence of genital types of human papillomavirus in normal pregnancy and in pregnant renal transplant recipients. Neuro Endocrinol Lett 27 4 (2006) 529-534
78. Lukasiewicz E., Martel J., Roujeau J.C., and Flahault A. Dermatology in private practice in France in 2000. Ann Dermatol Venereol 129 11 (2002) 1261-1265
79. Lukaszuk K., Liss J., Zalewski J., Roter M., Brzoska B., and Debniak J. Estimation of HPV infection presence in cytological smears in a group of asymptomatic women. Wiad Lek 54 9-10 (2001) 508-515
80. Jeng C.J., Phdl, Ko M.L., Ling Q.D., Shen J., Lin H.W., et al. Prevalence of cervical human papillomavirus in Taiwanese women. Clin Invest Med 28 5 (2005) 261-266
81. Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285 23 (2001) 2995-3002
82. Melnikow J., Nuovo J., Willan A.R., Chan B.K., and Howell L.P. Natural history of cervical squamous intraepithelial lesions: A meta-analysis. Obstet Gynecol 92 4 Pt 2 (1998) 727-735
83. Holowaty P., Miller A.B., Rohan T., and To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91 3 (1999) 252-258
84. Schlecht N.F., Platt R.W., Duarte-Franco E., Costa M.C., Sobrinho J.P., Prado J.C., et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95 17 (2003) 1336-1343
85. Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180 5 (1999) 1415-1423
86. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 7 (1998) 423-428
87. Molano M., Van den B.A., Plummer M., Weiderpass E., Posso H., Arslan A., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am J Epidemiol 158 5 (2003) 486-494
88. Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Bezemer P.D., et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358 9295 (2001) 1782-1783
89. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 24 (2001) 3106-3114
90. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet 366 9490 (2005) 991-998
91. Huang H.J., Huang S.L., Lin C.Y., Lin R.W., Chao F.Y., Chen M.Y., et al. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer 14 4 (2004) 639-649
92. Chen T.M., Chen C.A., Wu C.C., Huang S.C., Chang C.F., and Hsieh C.Y. The genotypes and prognostic significance of human papillomaviruses in cervical cancer. Int J Cancer 57 2 (1994) 181-184
93. Lai C.H., Huang H.J., Hsueh S., Chao A., Lin C.T., Huang S.L., et al. Human papillomavirus genotype in cervical cancer: A population-based study. Int J Cancer 120 9 (2007) 1999-2006
94. The human mortality database. wwwmortalityorg 2008 [cited 2008 April 16].
95. Ferlay J, Bray F., Pisani P., Parkin D.M. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC 2004 (IARC CancerBase No 5 v.2.0). Available from: URL: http://www-dep.iarc.fr/.
96. Bergeron C, Cartier I, Guldner L, Lassalle M, Savignoni A, Asselain B. Lésions précancéreuses et cancers du col de l'utérus diagnostiqués par le frottis cervical, Ile-de-France, enquête Crisap, 2002. Bulletin Epidémiologique Hebdomadaire 2005 Jan;(2):5-8.
97. Fender M., Schott J., Baldauf J.J., Muller J., Schlund E., and Dellenbach P. EVE, a regional campaign for the screening of cervical cancer. Organization, 7-years results and perspectives. Presse Med 32 33 (2003) 1545-1551